Vol. 4 No. 10 (2024): October
Reimbursement Reviews

Bimekizumab (Bimzelx)

decorative image of the issue cover

Published October 10, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses bimekizumab (BIMZELX), 160 mg/mL, solution for injection, subcutaneous injection.
  • Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.